Literature DB >> 25344422

Comparative effectiveness of pyruvate kinase M2 in bile, serum carbohydrate antigen 19-9, and biliary brushings in diagnosing malignant biliary strictures.

Udayakumar Navaneethan1, Vennisvasanth Lourdusamy, Earl Poptic, Jeffrey P Hammel, Madhusudhan R Sanaka, Mansour A Parsi.   

Abstract

BACKGROUND: The role of M2-PK (pyruvate kinase) in bile has not been studied in comparison with brushings and carbohydrate antigen (CA) 19-9 in the diagnosis of malignant biliary strictures. AIM: To compare the diagnostic accuracy of biliary M2-PK with cytology and serum CA 19-9
METHODS: In this prospective cross-sectional study, bile was aspirated in 74 patients (discovery and validation cohort) undergoing endoscopic retrograde cholangiopancreatography. Levels of M2-PK were measured in bile and compared to brushings for cytology and CA 19-9.
RESULTS: In the discovery cohort, the median bile M2-PK levels were significantly elevated in patients with malignant biliary strictures [187.9 U/l (interquartile range (IQR) 3.5, 3626.8)] compared to those with benign biliary conditions and primary sclerosing cholangitis [0 U/l (IQR 0, 15)] (P = 0.007). A M2-PK cutoff value of 109.1 U/l distinguished malignant from benign conditions with a sensitivity and specificity of 52.9 and 94.1 %, respectively, and area under curve (AUC) of 0.77. The sensitivity of CA 19-9 and brushings in diagnosing cancer was 52.9 % and 11.1 % and specificity 94.1 and 100 %, respectively. The presence of elevated M2-PK >109.1 U/l or CA 19-9 >33 U/ml or positive brushing was 88.2 % sensitive and 88.2 % specific, AUC of 0.89 in the diagnosis of malignancy. The diagnostic accuracy was confirmed in the validation cohort.
CONCLUSIONS: As a stand-alone factor, none of the markers were able to distinguish benign from malignant biliary strictures with a high sensitivity. However, a combination was highly sensitive in diagnosing malignant biliary strictures.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25344422     DOI: 10.1007/s10620-014-3397-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

2.  Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.

Authors:  Maiken Thyregod Joergensen; Niels H H Heegaard; Ove B Schaffalitzky de Muckadell
Journal:  Pancreas       Date:  2010-03       Impact factor: 3.327

3.  Vascular endothelial growth factor levels in bile distinguishes pancreatic cancer from other etiologies of biliary stricture: a pilot study.

Authors:  Udayakumar Navaneethan; Norma G Gutierrez; Ramprasad Jegadeesan; Preethi G K Venkatesh; Earl Poptic; Xiuli Liu; Madhusudhan R Sanaka; Sunguk Jang; John J Vargo; Mansour A Parsi
Journal:  Dig Dis Sci       Date:  2013-07-05       Impact factor: 3.199

Review 4.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.

Authors:  K S Goonetilleke; A K Siriwardena
Journal:  Eur J Surg Oncol       Date:  2006-11-09       Impact factor: 4.424

5.  Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.

Authors:  Maurizio Ventrucci; Antonio Cipolla; Chiara Racchini; Riccardo Casadei; Patrizia Simoni; Lucio Gullo
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

6.  Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer.

Authors:  Ivo Novotný; Petr Dítĕ; Milan Dastych; Anna Záková; Jan Trna; H Novotná; H Nechutová
Journal:  Hepatogastroenterology       Date:  2008 Jul-Aug

7.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

8.  CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.

Authors:  Daniele Marrelli; Stefano Caruso; Corrado Pedrazzani; Alessandro Neri; Eduardo Fernandes; Mario Marini; Enrico Pinto; Franco Roviello
Journal:  Am J Surg       Date:  2009-04-17       Impact factor: 2.565

9.  Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis.

Authors:  Yogesh Kumar; Kurinchi Gurusamy; Vineet Pamecha; Brian R Davidson
Journal:  Pancreas       Date:  2007-08       Impact factor: 3.327

Review 10.  Current endoscopic approach to indeterminate biliary strictures.

Authors:  David W Victor; Stuart Sherman; Tarkan Karakan; Mouen A Khashab
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

View more
  8 in total

1.  Lateral flow assay for carbohydrate antigen 19-9 in whole blood by using magnetized carbon nanotubes.

Authors:  Yan Huang; Yongqiang Wen; Kwaku Baryeh; Sunitha Takalkar; Michelle Lund; Xueji Zhang; Guodong Liu
Journal:  Mikrochim Acta       Date:  2017-08-25       Impact factor: 5.833

Review 2.  Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study.

Authors:  Fang Bao; Jiayue Liu; Haiyang Chen; Lu Miao; Zhaochao Xu; Guixin Zhang
Journal:  Cancers (Basel)       Date:  2022-08-13       Impact factor: 6.575

3.  The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas.

Authors:  Jayabal Pandiaraja; Subramanian Viswanathan; Thomas Babu Antomy; Sathyamoorthy Thirumuruganand; Dhandapani Subramanian Kumaresan
Journal:  J Clin Diagn Res       Date:  2016-03-01

4.  Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.

Authors:  Gyem Tshering; Palden Wangyel Dorji; Wanna Chaijaroenkul; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2018-04-05       Impact factor: 2.345

Review 5.  Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy.

Authors:  Margaret G Keane; Amar Shah; Stephen P Pereira; Deepak Joshi
Journal:  F1000Res       Date:  2017-09-05

6.  Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis.

Authors:  Joy Cuenco; Natascha Wehnert; Oleg Blyuss; Anna Kazarian; Harry J Whitwell; Usha Menon; Anne Dawnay; Michael P Manns; Stephen P Pereira; John F Timms
Journal:  Oncotarget       Date:  2018-04-03

7.  BIRC7 and STC2 Expression Are Associated With Tumorigenesis and Poor Outcome in Extrahepatic Cholangiocarcinoma.

Authors:  Jiequn Li; Zhulin Yang; Shengfu Huang; Daiqiang Li
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

8.  Lateral Flow Immunoassay Based on Time-Resolved Fluorescence Microspheres for Rapid and Quantitative Screening CA199 in Human Serum.

Authors:  Xueshima Jiao; Tao Peng; Zhanwei Liang; Yalin Hu; Bo Meng; Yang Zhao; Jie Xie; Xiaoyun Gong; You Jiang; Xiang Fang; Xiaoping Yu; Xinhua Dai
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.